Introduction {#s1}
============

Description of the Condition {#s1_1}
----------------------------

Fatigue is a condition of lacking the energy and motivation in responding to physical activity, emotional stress, boredom or insufficient sleep ([@B4]). It is a complex, multidimensional symptom that is prevalent in the general population ([@B35]). The cause of fatigue is unknown. The severity of fatigue varies greatly among individuals. Although fatigue does not lead to death, it has negative impacts on many areas of daily life ([@B3]). "Feeling weak all over for much of the time" was regarded as one of the most important symptoms ([@B46]). Most physical illnesses are associated with fatigue, such as many chronic diseases, namely anaemia, emphysema, asthma, and arthritis ([@B10]). Fatigue is a clinical challenge because its study of etiology, risk factors, and pathophysiology are still at an early stage. The goal of treatment is to treat symptoms and improve outcomes rather than to provide clear treatment ([@B1]).

Description of the Intervention {#s1_2}
-------------------------------

Different interventions have been used in treating fatigue ([@B74]). Nowadays, treatments commonly focus on muscle pain, sleep disorders, and emotional symptoms. Cognitive Behavior Therapy (CBT), various forms of exercise, as well as enhancement of coping ability, are standard treatment options. In addition, caregiver prescribed or self-administered medication are still common ([@B36]). It is indicated that no universal western medicine treatment can be recommended ([@B12]). Interventions which include CBT and graded exercise therapy have shown promising results ([@B74]). However, patients seem to be skeptical about CBT, who claimed that CBT and graded exercise for fatigue were neither effective nor safe ([@B68]). Recently, various forms of complementary and alternative medicine (CAM) have been widely used in fatigue such as herbal medicine, cheirapsis, balanced nutrition, and acupuncture ([@B36]). In particular, *Panax ginseng* C.A. Mey (PG) has been a rising utilization in treating fatigue in Asia and elsewhere around world. Based on traditional Chinese medicine and herbal philosophy, PG is considered as an adaptation to help restore body balance ([@B3]). *Panax ginseng* C.A. Mey is believed to improve overall quality of life (QoL), including energy and vitality, particularly during times of fatigue or stress ([@B80]).

How the Intervention Might Work {#s1_3}
-------------------------------

*Panax ginseng* C.A. Mey has direct effects on the central nervous system (CNS), including cognition, sleep disorders, depression, pain, and the ability to regulate inflammatory cytokines ([@B80]). To date, numerous active compounds have been identified such as ginsenosides, ginseng polysaccharides, and ginseng protein. Ginsenosides, the most important ingredients of ginseng, have been proved with various pharmacological activities such as anti-fatigue, anti-oxidation, neuroprotection, anti-inflammation, and anti-diabetes. Ginsenoside Rg3 (Rg3) is one of the most abundant ginsenosides. It may improve exercise performance and increase fatigue resistance by enhancing deacetylase activity of silent information regulator of transcription 1 (SIRT1) and inhibiting the transcriptional activity of p53 ([@B78]). Ginseng polysaccharides have anti-fatigue activity probably by mobilizing triglyceride (TG) or fat during exercise, or by changing the activities oflactic dehydrogenase (LDH), malondialdehyde (MDA) and glutathione peroxidase (GPH-Px) to avoid lipid oxidation and protect corpuscular membrane ([@B82]). Ginseng proteins could resist fatigue through retarding the accumulation of blood lactate (BLA) and blood urea nitrogen (BUN), enhancing hepatic glycogen levels, and improving the ability of antioxidant enzymes ([@B60]).

Why It Is Important to Do This Review {#s1_4}
-------------------------------------

*Panax ginseng* C.A. Mey is one of the most widely used plant products worldwide which has been used in oriental countries for thousands of years ([@B82]). Based on a comprehensive collection of clinical trials, systematic review can perform comprehensive analysis and statistical processing on qualified studies to form relatively reliable results, which can guide clinical decision-making. In addition, systematic review can solve the following clinical problems: research on the effectiveness of treatment, evaluation of diagnostic methods, prognosis estimation, analysis of the cost and benefit of treatment. Up to now, at least 2 systematic reviews have been conducted to evaluate efficacy and safety of *Panax ginseng* C. A. Mey and its compounds (PGC) for fatigue ([@B4]; [@B3]). However, the results of these reviews are inconclusive because of methodological flaws in their included primary studies. Cochrane group have developed an extensive set of guide lines for systematic reviews. These "not-so-good" studies were excluded with a strict process ([@B75]). In addition, the efficacy and mechanisms of PGC in fatigue animal models have not been systematically evaluated yet. Systematic review of animal researches is indispensable in the process of drug development and elucidation of the physiological and pathological mechanisms ([@B83]). Preclinical research is the key to convert preclinical data into clinical data. In addition, systematic review of animal research is a more economic and ethical approach, which can integrate preclinical evidence, help reduce unnecessary sacrifice of laboratory animals, and prevent ineffective or less informative research ([@B84]). As we all know, there is a gap between clinical research and clinical practice. More communication is needed between animal researchers and clinical researchers. Systematic review of animal experiments can lead to better collaboration between research groups and encourage the use of iterative methods to improve the relevance of animal models to clinical trial design. If the model cannot well simulate the clinical situation, it can be adjusted accordingly. In addition, as in human research, systematic review helps to identify and improve behavioral and reporting deficiencies in animal research [@B58]. Systematic review can effectively integrate preclinical comprehensive evidence and guide potential clinical translation. Thus, the aim of present study was to systematically summarize and critically evaluate the data from randomized control trials (RCTs) and animal studies of PGC for fatigue.

Methods {#s2}
=======

Search Strategy {#s2_1}
---------------

This study followed the PRISMA statement ([@B66]). EMBASE, PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP database (VIP), China Biology Medicine Database (CBM) and Wangfang database were electronically searched from their inception to August 2019. The following keywords were used: "fatigue OR Lassitude lethargy OR exhaustion OR weariness OR tiredness" and "panax OR Ginseng OR renshen" in Chinese or in English. All searches were limited to animal studies and clinical trials.

Eligibility Criteria {#s2_2}
--------------------

The prespecified inclusion criteria of RCTs listed below: (1) RCTs that evaluated the effectiveness and safety of PGC for fatigue; (2) the Cochrane risk of bias (ROB) tool met at least 4 out of the 7 domains; (3) Subjects had chronic fatigue syndrome (CFS) or healthy adults after exercise; Subjects were classified as CFS-like according to Evaluation and Classification of Unexplained Chronic Fatigue (ECUCF) ([@B26]); (4) PGC as monotherapy was used as an intervention in the treatment group, and interventions for control group were placebo or vehicle treatment; (5) The primary outcome measures were scales of fatigue and/or objective evaluation criteria (e.g. physical performance, biochemical parameters). The secondary outcome measures were clinical effect according to fatigue scales and adverse events. The exclusion criteria were prespecified as follows: (1) fatigue caused by a medical condition, or withdrawal from medicines or substance; (2) duplicate publications and no available data.

The inclusion criteria of animal studies were prespecified as follows: (1) PGC for fatigue animal models was established by forced movement; (2) The interventions of treatment group were PGC at any dose and control group were nonfunctional liquid (normal saline) or no treatment; and (3) The primary outcome measures were forced movement time and/or serum biochemical parameters and/or skeletal muscle biochemical parameters and/or liver biochemical parameters and/or brain tissue biochemical parameters. The secondary outcome measures were body weight, organ index (organ weight/body weight) and possible mechanisms of PGC for anti-fatigue. The exclusion criteria were predefined as follows: (1) not fatigue model; (2) combined use of other drugs; and (3) no available data, duplicate publications, and lack of control group.

Data Extraction {#s2_3}
---------------

Two independent researchers extracted the details from the included RCTs and animal studies according to two standardized data extraction forms, respectively. There are many manners for including outcomes, such as peak time point, last time point, and same time point. There is undeniable that any manner will lead to bias. In order to minimize bias, inclusion criteria were prespecified as follows: The result of the peak time point was included when the data were expressed at different times. If meta-analysis data were lost or expressed graphically, we would try to contact the author for more information. When no response was received, we used digital ruler software or exclusion software to measure data from charts. If the data in the primary RCT were missing or merely illustrated graphically, an effort was launched to obtain further information through contacting the authors. If failed, the digital ruler software was used for measuring data from the graphs or excluded.

Quality Assessment {#s2_4}
------------------

The methodological quality of the included RCTs was evaluated by using the Cochrane Collaboration\'s tool. The RoB of the included animal studies was assessed using 10-item quality checklist of the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES) with minor modification. Divergences were well settled by correspondence author (GZ).

Statistical Analysis {#s2_5}
--------------------

Analysis was conducted with RevMan 5.3 and Stata SE software. Continuous outcomes were presented as mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval (CI). Dichotomous outcomes were presented risk ratio (RR) or odds ratio (OR) with 95% CI. Probability values P \<0.05 were considered significant. In order to estimate heterogeneity across studies, we used I^2^ - statistic test. An I^2^ value greater than 50% was considered as having substantial heterogeneity. When substantial heterogeneity was not observed, the fixed-effects model was reported. On the contrary, the random-effects model was reported. Simultaneously, considering the differences in subjects, interventions, and treatments, we used the Z-test for subgroup analysis. P \<0.05 was considered to be statistically significant. If an outcome contained more than 10 RCTs, funnel plots, and Egger\'s test were used to examine publication bias.

Results {#s3}
=======

Study Selection {#s3_1}
---------------

A total of 1331 relevant literatures were retrieved from the database, of which 667 were considered duplicates. Of the remaining 664 articles, qualified RCTs and animal experiments should be selected separately. For RCTs, 362 articles were eliminated because of reviews, case report, or animal studies. After scanning the remaining 302 full-text articles, 294 studies were excluded by reasons that they were (1) combined with other disease; (2) combined with other herbal treatment(s) in the intervention group; (3) no data available; (4) not real RCTs or quasi-RCTs; or (5) with the less than 4 domains "yes" according to the Cochrane RoB tool. Eventually, 8 RCTs were selected ([**Figure 1A**](#f1){ref-type="fig"}). For animal studies, 243 studies including clinical trials, case reports or review articles were excluded. Through full-text evaluation of the remaining 421 studies, 391 were excluded for at least one of the following reasons: (1) lack of control group; (2) inappropriate fatigue model; (3) combined with other herbal treatment(s) in the intervention group; (4) unavailable data. Ultimately, 30 animal studies were included ([**Figure 1B**](#f1){ref-type="fig"}).

![**(A)** Flow diagram of randomized control trials selection process. **(B)** Flow diagram of animal experiments selection process.](fphar-11-01031-g001){#f1}

Study Characteristics {#s3_2}
---------------------

### Randomized Control Trials {#s3_2_1}

All involved studies were published in English. All 8 studies ([@B27]; [@B15]; [@B17]; [@B16]; [@B31]; [@B34]; [@B41]; [@B44]) were RCTs, which involved a total of 678 participants, and the sample size ranged from 19 to 218. Five RCTs ([@B27]; [@B31]; [@B34]; [@B41]; [@B44]) involved 615 participants with CFS. The diagnostic criteria of patients with CFS were based on ECUCF. The rest of 3 RCTs ([@B15]; [@B17]; [@B16]) involved 63 healthy adults after exercise. They were published from 1996 to 2016 and conducted in America (n = 4) ([@B15]; [@B17]; [@B16]; [@B31]), South Korea (n = 3) ([@B34]; [@B41]; [@B44]), and France (n = 1) ([@B27]). The duration of treatment ranged from 4 to 8 weeks. They used PGC as intervention of experimental group. The placebo-control was used in all 8 studies. Five studies ([@B15]; [@B17]; [@B16]; [@B34]; [@B41]) used objective evaluation criteria, including metabolic response and physical performance as outcome measure. Five studies ([@B27]; [@B31]; [@B34]; [@B41]; [@B44]) used self-reported fatigue measures, including Rand Vitality Index (RVI), Mood and Anxiety Symptom Questionnaire (MASQ), fatigue duration, checklist individual strength (CIS), Numeric Scale (NRS), Visual Analogue Scale (VAS), Visual Analogue Fatigue Scale (VAFS), Revised Piper Fatigue Scale (RPFS), Short-Form Health Survey (SF-36), Fatigue score, and clinical effect as outcome measure. The general characteristics of the 8 included articles were illustrated in [**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}.

###### 

Characteristics of the included randomized control trials.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Authors; year   Study design   Gender (male/female); mean/range age(years)   Interventions   Course of treatment              Outcome measure   Intergroup differences                                                                                                                     
  --------------------- -------------- --------------------------------------------- --------------- -------------------------------- ----------------- ------------------------ ----------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------
  [@B15]                RCT            10\                                           9\              G115 (200 mg qd) po              placebo           8 weeks                  blood lactic acidoxygen uptakeRERVEheart rate                                                                     P \> 0.05P \> 0.05P \> 0.05P \> 0.05P \> 0.05
                                       21--35                                        21--35                                                                                                                                                                                                        

  [@B17]                RCT            9\                                            10\             G115 (400 mg qd) po              placebo           8 weeks                  peak anaerobic power outputmean anaerobic power outputrate of fatigueimmediate postexerciserecovery heart rates   P \> 0.05P \> 0.05P \> 0.05P \> 0.05P \< 0.05
                                       27.1 ± 7.0                                    23.6 ± 5.4                                                                                                                                                                                                    

  [@B16]                RCT            15\                                           10\             G115 (400 mg qd) po              placebo           8 weeks                  Peak power outputmean power outputHeart rate recovery                                                             P \< 0.01P \< 0.01P \> 0.05
                                       26.3 ± 1.9                                    26.1 ± 1.7                                                                                                                                                                                                    

  [@B31]                RCT            30/6\                                         31/9\           extract of PG (800 mg bid) po    placebo           2 months                 Fatigue severityRVIMASQFatigue durationAdverse event                                                              P \< 0.05P \< 0.05P \< 0.05P \< 0.05P \> 0.05
                                       21--34 0\                                     21--34 1\                                                                                                                                                                                                     
                                       35--49 18\                                    35--49 22\                                                                                                                                                                                                    
                                       50--65 18                                     50--65 7                                                                                                                                                                                                      

  [@B41]                RCT            23/49\                                        15/62\          URSA (1\# 50 mg bid) po          placebo           4 weeks                  CIS scoreALTASTγ‐GTAdverse event                                                                                  P \> 0.05P \< 0.05P \> 0.05P \> 0.05P \> 0.05
                                       \< 29 27\                                     \< 29 23\                                                                                                                                                                                                     
                                       30--39 25\                                    30--39 36\                                                                                                                                                                                                    
                                       40--49 16\                                    40--49 13\                                                                                                                                                                                                    
                                       \> 50 4                                       \> 50 3                                                                                                                                                                                                       

  [@B34]                RCT            21/69\                                        6/24\           PG (1, 2 g qd) po                placebo           4 weeks                  NRSVASROSMDAGSHGSH-RdAdverse event                                                                                P \> 0.05P \< 0.05P \< 0.05P \< 0.05P \< 0.05P \< 0.05P \> 0.05
                                       39.5                                          39.5                                                                                                                                                                                                          

  [@B44]                RCT            5/21\                                         7/19\           EMGE (500 mg bid) po             placebo           4 weeks                  VAFSRPFSSF-36Adverse event                                                                                        P \< 0.01P \> 0.05P \> 0.05P \> 0.05
                                       60.1 ± 4.44                                   62.1 ± 5.18                                                                                                                                                                                                   

  [@B27]                RCT            34/75\                                        34/75\          Pharmaton Capsule (1\# bid) po   placebo           42 days                  Fatigue scoreAdverse event                                                                                        P=0.019P \> 0.05
                                       37.6                                          38.8                                                                                                                                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CIS, checklist individual strength; GSH, glutathione; GSH-Rd, glutathione reductase; G115, standardized P. ginseng C.A. Mey concentrate;MASQ, Mood and Anxiety Symptom Questionnaire; MDA, malondialdehyde; NRS, self-rating numeric scale; PG, P. ginseng C.A. Mey; RER, respiratory exchange ratio; ROS, reactive oxygen species; RPFS, Revised Piper Fatigue Scale; RVI, Rand Vitality Index; SF-36, Short-Form Health Survey; VAS, visual analog scale; VAFS, visual analog fatigue scale; VE, minute ventilation.

###### 

Statement of the characteristic of *Panax ginseng* C. A. Mey and its compounds(a).

  First Authors; year   Drugs;                                     Approach to achieving                                          Chemical analysis   Composition
  --------------------- ------------------------------------------ -------------------------------------------------------------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  [@B15]                G115                                       Pharmaten Ltd., Lugano, Switzerland                            included-HPLC       Contain 4% ginsenosides(Rgl 0.548%, Re 0.352%, Rf 0.270%, Rg2 0.065%, Rbl 1.338%, Rc 0.714%, Rb2 0.567%, Rd 0.286%) HPLC data from F. [@B64].
  [@B17]                G115                                       Pharmaten Ltd., Lugano, Switzerland                            included-HPLC       Contain 4% ginsenosides(Rgl 0.548%, Re 0.352%, Rf 0.270%, Rg2 0.065%, Rbl 1.338%, Rc 0.714%, Rb2 0.567%, Rd 0.286%) HPLC data from F. [@B64].
  [@B16]                G115                                       Pharmaten Ltd., Lugano, Switzerland                            included-HPLC       Contain 4% ginsenosides(Rgl 0.548%, Re 0.352%, Rf 0.270%, Rg2 0.065%, Rbl 1.338%, Rc 0.714%, Rb2 0.567%, Rd 0.286%) HPLC data from F. [@B64].
  [@B31]                extract ofPG                               Frontier Herbs of Norway, IA., Norway                          included-HPLC       Contain 0.112%eleutheroside B and eleutheroside E
  [@B41]                URSA Complex (contain dried PG extract);   not reported                                                   included-HPLC       Contain dried ginseng extracts 50 mg
  [@B34]                bespoke 20% ethanol extract of PG;         Guryoung Pharmaceutical Company, Ltd., Cheorwon, South Korea   included-HPLC       Contain 2% ginsenosides (Rb3 0.633%, Rb1 0.514%, Rb2 0.36%, Rc 0.261%, Rg3 0.108%, Rd 0.043%, Rh2 0.0002%) HPLC data from [@B34].
  [@B44]                Enzyme-modified ginseng extract (EMGE);    not reported                                                   included-HPLC       Rg1, Rh1, Rb1, Rg3(S), Rg3(R), Compound K, Rh2(S), Rh2(R);(similar to G115 by HPLC) HPLC data from [@B44].
  [@B27]                Pharmaton Capsule (contain G115);          Pharmaten Ltd., Lugano, Switzerland                            included-HPLC       Contain 4% ginsenosides (Rgl 0.548%, Re 0.352%, Rf 0.270%, Rg2 0.065%, Rbl 1.338%, Rc 0.714%, Rb2 0.567%, Rd 0.286%) HPLC data from F. [@B64].

G115, standardized P. ginseng C.A. Mey concentrate; HPLC: high-performance liquid chromatography; PG, Panaxginseng C.A. Mey.

### Animal Studies {#s3_2_2}

Nine studies ([@B11]; [@B33]; [@B60]; [@B71]; [@B54]; [@B5]; [@B51]; [@B82]; [@B14]) were published in English and 21 studies ([@B20]; [@B21]; [@B22]; [@B48]; [@B55]; [@B23]; [@B24]; [@B25]; [@B56]; [@B57]; [@B76]; [@B9]; [@B28]; [@B77]; [@B65]; [@B81]; [@B49]; [@B72]; [@B50]; [@B63]; [@B79]) were published in Chinese between 2005 and 2019. All 30 studies involved a total of 2249 animals. Twelve studies ([@B20]; [@B21]; [@B22]; [@B55]; [@B23]; [@B24]; [@B25]; [@B56]; [@B57]; [@B76]; [@B9]; [@B50]) used Sprague Dawley (SD) rats; 1 study ([@B65]) used Wistar rats; 8 studies ([@B11]; [@B33]; [@B71]; [@B54]; [@B5]; [@B51]; [@B82]; [@B14]) used Institute of Cancer Research (ICR) mice; 6 studies ([@B48]; [@B77]; [@B81]; [@B60]; [@B72]; [@B63]) used Kunming (KM) mice; 3 studies ([@B28]; [@B49]; [@B79]) used unknown breed mice. Twenty-seven studies ([@B20]; [@B21]; [@B22]; [@B48]; [@B55]; [@B23]; [@B24]; [@B25]; [@B56]; [@B57]; [@B76]; [@B9]; [@B28]; [@B11]; [@B65]; [@B33]; [@B71]; [@B49]; [@B72]; [@B54]; [@B5]; [@B50]; [@B63]; [@B79]; [@B51]; [@B82]; [@B14]) used male animals, 2 studies ([@B60]; [@B81]) used both female and male rats, and 1 study ([@B77]) did not mention gender of animals. The weight of adult rats varied between 160 and 260 g and mice between 16 and 28 g. Anesthetic was mentioned in 1 study ([@B9]). Ginsenosides were used in 18 studies ([@B20]; [@B21]; [@B22]; [@B48]; [@B55]; [@B23]; [@B24]; [@B25]; [@B56]; [@B57]; [@B76]; [@B9]; [@B65]; [@B49]; [@B54]; [@B72]; [@B50]; [@B79]), ginseng in 6 studies ([@B11]; [@B28]; [@B33]; [@B81]; [@B63]; [@B51]), ginseng oligopeptides in 2 studies ([@B5]; [@B14]), ginseng polysaccharides in 2 studies ([@B71]; [@B82]) and ginseng protein in 2 studies ([@B77]; [@B60]). Thirteen fatigue models ([@B20]; [@B21]; [@B22]; [@B55]; [@B23]; [@B24]; [@B25]; [@B56]; [@B57]; [@B76]; [@B9]; [@B33]; [@B50]) were produced by Horizontal treadmill exercise, 10 models ([@B48]; [@B28]; [@B77]; [@B81]; [@B49]; [@B54]; [@B72]; [@B63]; [@B79]; [@B51]) by weight-loaded swimming test (WLST), 6 models ([@B65]; [@B60]; [@B71]; [@B5]; [@B82]; [@B14]) by Forced swimming test (FST) and 3models ([@B11]; [@B54]; [@B63]) by Rota-rod test. The non-functional liquid, normal saline or no treatment control was introduced in all 30 studies. Thirteen studies ([@B48] [@B77]; [@B65]; [@B60]; [@B81]; [@B49]; [@B54]; [@B72]; [@B5]; [@B63]; [@B79]; [@B51]; [@B14]) utilized swimming time as outcome measure, and climbing time in 1 study ([@B63]). Serum biochemical parameters, including BLA, BUN, glucose (GLU), creatine kinase (CK), MDA, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and LDH were reported in 21 studies ([@B22]; [@B48]; [@B56]; [@B11]; [@B28]; [@B77]; [@B65]; [@B33]; [@B60]; [@B71]; [@B81]; [@B49]; [@B54]; [@B72]; [@B5]; [@B50]; [@B63]; [@B79]; [@B51]; [@B82]; [@B14]); skeletal muscle biochemical parameters, including glycogen, MDA, SOD, catalase (CAT), and GSH-Px in 13 studies ([@B48]; [@B23]; [@B24]; [@B25]; [@B57]; [@B76]; [@B28]; [@B81]; [@B72]; [@B5]; [@B50]; [@B51]; [@B14]); liver biochemical parameters, including glycogen, MDA, SOD, and GSH-Px in 14 studies ([@B22]; [@B56]; [@B28]; [@B77]; [@B33]; [@B60]; [@B81]; [@B49]; [@B72]; [@B5]; [@B63]; [@B79]; [@B51]; [@B14]); brain tissue biochemical parameters, including acetylcholine (Ach), dopamine (DA), gamma-aminobutyric acid (GABA), 5-hydroxytryptamine (5-HT) in 5 study ([@B20]; [@B21]; [@B22]; [@B9]; [@B50]); and body weight in 7 studies ([@B48]; [@B77]; [@B65]; [@B33]; [@B5]; [@B50]; [@B63]). Approach to achieving of PGC was reported in 15 studies ([@B20]; [@B21]; [@B22]; [@B48]; [@B55]; [@B23]; [@B24]; [@B25]; [@B56]; [@B57]; [@B76]; [@B9]; [@B11]; [@B65]; [@B33]; [@B71]; [@B49]; [@B54]; [@B72]; [@B5]; [@B50]; [@B63]; [@B82]; [@B14]) and quality control of PGC was reported in 8 studies ([@B22]; [@B25]; [@B9]; [@B71]; [@B49]; [@B54]; [@B82]; [@B14]). [**Tables 3**](#T3){ref-type="table"} and [**4**](#T4){ref-type="table"} show the characteristics of included publications.

###### 

Characteristics of the included animal studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (years)   Species\          Anesthetic                               Model (method)                                                              Experimental group (drugs, concentration, administration, duration)   Control group                     Outcome measure                                                                                                                                                                                                                                                                             Intergroup differences\*
                  Sex\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                  Weight\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                  N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  --------------- ----------------- ---------------------------------------- --------------------------------------------------------------------------- --------------------------------------------------------------------- --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B77]          KM mice\          --                                       weight-loaded swimming (WLS) test                                           ginseng protein (0.1, 0.2, 0.4 g/kg) ig, 30 days                      Distilled water for same volume   Mice body weightSwimming time in miceBLALiver glycogenSerum urea nitrogen                                                                                                                                                                                                                   P\>0.05P\>0.05P\<0.05P\>0.05P\>0.05
                  NG\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                  18--22 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                  240                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B70]          ICR mice\         --                                       Forced swimming test                                                        WGP (50,100,200 mg/kg)\                                               NS for same volume                Serum GLUSerum TGSerum CKSerum LDHSerum MDASerum SODSerum GSH-Px                                                                                                                                                                                                                            P\<0.01P\<0.01P\<0.05P\<0.05P\<0.001P\<0.05P\<0.05
                  M\                                                                                                                                     WGPA(40,100,160,200 mg/kg)\                                                                                                                                                                                                                                                                                                                                                                         
                  (11--12 weeks)\                                                                                                                        WGPN(40,100,160,200 mg/kg) ig, 15 days                                                                                                                                                                                                                                                                                                                                                              
                  104                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B71]          ICR mice\         --                                       Forced swimming test                                                        WGPA (200 mg/kg)\                                                     NS for same volume                Serum MDASerum SODSerumGSH-PxSerum LDH                                                                                                                                                                                                                                                      P\<0.001P\<0.01P\<0.01P\<0.05
                  M\                                                                                                                                     WGPA-A(200 mg/kg)\                                                                                                                                                                                                                                                                                                                                                                                  
                  (11--12 weeks)\                                                                                                                        WGPA-N(200 mg/kg) ig, 15 days                                                                                                                                                                                                                                                                                                                                                                       
                  104                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B65]          Wistar rat\       --                                       Forced swimming test                                                        PTS (25, 50, 100 mg/kg) ig, 7 weeks                                   NS for same volume                Mice body weightSwimming time in miceSerum GLUSerum urea nitrogenBlood lactic acid                                                                                                                                                                                                          P\>0.05P\<0.05P\<0.05P\<0.05P\<0.05
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  180--220 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  60                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B76]          SD rat\           --                                       Horizontal treadmill exercise                                               Ginsenoside Rb1(50 mg/kg) ig, 14 days                                 NS for same volume                Skeletal muscle MDASkeletal muscle SOD                                                                                                                                                                                                                                                      P\<0.01P\<0.05
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  180--200 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B23]          SD rat\           --                                       Horizontal treadmill exercise                                               Ginsenoside (50 mg/kg)\                                               NS for same volume                Calcium content in skeletal muscle cellMitochondrial membrane potentialSkeletal muscle MDASkeletal muscle SODSkeletal muscle GLU                                                                                                                                                            P\<0.05P\<0.05P\<0.05P\<0.05P\<0.05
                  M\                                                                                                                                     Ginsenoside Rb1(50 mg/kg) ig, 14 days                                                                                                                                                                                                                                                                                                                                                               
                  180--220 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B21]          SD rat\           --                                       Horizontal treadmill exercise                                               Ginsenoside (50 mg/kg)\                                               NS for same volume                Hypothalamus AchHypothalamus DAHypothalamus 5-HTHypothalamus GABA                                                                                                                                                                                                                           P\<0.01P\<0.01 or P\<0.05P\<0.01P\<0.01
                  M\                                                                                                                                     Ginsenoside Re (50 mg/kg) ig, 14 days                                                                                                                                                                                                                                                                                                                                                               
                  180--220 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B50]          SD rat\           --                                       Horizontal treadmill exercise                                               Ginsenoside Rg1(30 mg/kg) ig, 8 weeks                                 NS for same volume                Mice body weightExhaustion timeSkeletal muscle SODSkeletal muscle GSH-PxSkeletal muscle CATSkeletal muscle MDASkeletal muscle carbonylation protein contentBrain tissue SODBrain tissue GSH-PxBrain tissue CATBrain tissue MDABrain tissue carbonylation protein contentBlood lactic acid   P\>0.05P\<0.01P\<0.01P\<0.05P\<0.05P\<0.05P\<0.05P\<0.01P\<0.05P\<0.05P\>0.05P\<0.0513. P\>0.05
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  240 ± 20 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B24]          SD rat\           --                                       Horizontal treadmill exercise                                               Ginsenoside Rb1(50 mg/kg)\                                            NS for same volume                Hypothalamus AchHypothalamus DAHypothalamus 5-HTHypothalamus GABA                                                                                                                                                                                                                           P\<0.01P\<0.01P\<0.01P\<0.01
                  M\                                                                                                                                     Ginsenoside Rg1(50 mg/kg) ig, 14 days                                                                                                                                                                                                                                                                                                                                                               
                  180--220 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B72]          KM mice\          --                                       weight-loaded swimming (WLS) test                                           Ginsenoside Rg1(5, 10, 20, 40, 80 mg/kg) ig, 2 weeks                  NS for same volume                Swimming timeBlood lactic acidSerum BUNSerum GLUMuscle glycogenHepatic glycogen                                                                                                                                                                                                             P\>0.05P\>0.05P\>0.05P\>0.05P\<0.01P\<0.05
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  20 ± 2 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                  180                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B79]          mice\             --                                       weight-loaded swimming (WLS) test                                           Ginsenoside (0.8, 1.6, 3.2 g/kg) ig, 28 days                          distilled water for same volume   Serum BUNSerum LDHSerum BLASerum CKHepatic glycogenLiver MDALiver SODLiver GSH-PxSwimming time                                                                                                                                                                                              P\<0.05P\<0.05P\<0.05P\<0.05P\<0.05P\<0.05P\<0.05P\<0.05P\<0.05
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  19--22 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                  80                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B49]          mice\             --                                       weight-loaded swimming (WLS) test                                           Ginsenoside (0.8, 1.6, 3.2 g/kg) ig, 28 days                          distilled water for same volume   Serum BUNSerum LDHSerum BLASerum CKHepatic glycogenLiver MDALiver SODLiver GSH-PxSwimming time                                                                                                                                                                                              P\<0.001P\<0.01P\<0.05P\<0.001P\<0.01P\<0.01P\>0.05P\>0.05P\<0.01
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  18--22 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                  40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B21]          SD rat\           --                                       Horizontal treadmill exercise                                               Ginsenoside Re(50 mg/kg) ig, 14 days                                  NS for same volume                1.Serum MDALiver MDASkeletal muscle MDASerum SODLiver SODSkeletal muscle SOD                                                                                                                                                                                                                P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  180--220 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B25]          SD rat\           --                                       Horizontal treadmill exercise                                               Ginsenoside Rg1(50 mg/kg) ig, 14 days                                 NS for same volume                Calcium content in skeletal muscle cellMitochondrial membrane potentialSkeletal muscle SODSkeletal muscle MDA                                                                                                                                                                               P\<0.01P\<0.01P\<0.01P\<0.01
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  180--220 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B56]          SD rat\           --                                       Horizontal treadmill exercise                                               Ginsenosides (50 mg/kg) ig, 14 days                                   NS for same volume                Calcium content in skeletal muscle cellMitochondrial membrane potentialSkeletal muscle SODSkeletal muscle MDA                                                                                                                                                                               P\<0.01P\<0.01P\<0.01P\<0.01
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  180--220 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B9]           SD rat\           Celiac anesthesia with chloral hydrate   Horizontal treadmill exercise                                               Ginsenosides (70 mg/kg) ig, 8 weeks                                   NS for same volume                Hippocampus tissue GABAHippocampus tissue AchHippocampus tissue NEHippocampus tissue DAHippocampus tissue 5-HTDA/5-HT                                                                                                                                                                       P\<0.05P\<0.05P\<0.05P\<0.05P\<0.05P\<0.05
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  160--200 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  45                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B55]          SD rat\           --                                       Horizontal treadmill exercise                                               Ginsenosides(50 mg/kg)\                                               NS for same volume                Hippocampus tissue GABAHippocampus tissue DAHippocampus tissue 5-HTHippocampus tissue Ach                                                                                                                                                                                                   P\<0.01P\<0.05P\<0.01P\<0.05
                  M\                                                                                                                                     Ginsenoside Rg1(50 mg/kg) ig, 14 days                                                                                                                                                                                                                                                                                                                                                               
                  180--220 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B48]          KM mice\          --                                       weight-loaded swimming (WLS) test                                           Pseudo- ginsenoside GQ(PGQ) (0.2, 0.4, 0.8 g/kg) ig, 5 weeks          NS for same volume                Mice body weightSwimming time in miceBlood lactic acidSerum BUNSerum LDHMuscle glycogen                                                                                                                                                                                                     P\<0.05P\<0.01P\<0.05P\<0.05P\<0.05P\<0.05
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  18--22 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                  80                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B22]          SD rat\           --                                       Horizontal treadmill exercise                                               Ginsenoside Rb1(50 mg/kg)\                                            NS for same volume                Hippocampus tissue DAHippocampus tissue 5-HTHippocampus tissue GABAHippocampus tissue Ach                                                                                                                                                                                                   1.P\<0.05P\<0.05P\<0.01P\<0.01
                  M\                                                                                                                                     Ginsenoside Re(50 mg/kg) ig, 14 days                                                                                                                                                                                                                                                                                                                                                                
                  180--220 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B57]          SD rat\           --                                       Horizontal treadmill exercise                                               Ginsenoside Rb1 (50 mg/kg) ig, 14 days                                NS for same volume                Serum MDASerum SODLiver MDALiver SOD                                                                                                                                                                                                                                                        P\<0.01P\<0.01P\<0.014. P\<0.01
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  180--220 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                  30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B5]           ICR mice\         --                                       Forced Swimming Test                                                        GOP (125, 250, 500 mg/kg) ig, 30 days                                 Distilled water for same volume   Mice body weightSwimming time in miceSerum LDHSerum Urea NitrogenHepatic GlycogenBlood Lactic Acidskeletal muscle SODskeletal muscles CATskeletal muscles MDANRF-1TFAMmtDNA                                                                                                                 P\>0.05P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.05P\<0.05P\<0.05
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  18--22 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                  240                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B54]          ICR mice\         --                                       weight-loaded swimming (WLS) test and Rota-rod test                         PPD (5, 10 mg/kg)\                                                    Distilled water for same volume   Swimming timeSerum corticosteroneSerum GLUSerum lactateSerum LDHSerum FFASerum creatinineSerum corticosteroneSerum lactateSerum FFASerum creatinine                                                                                                                                         P\<0.05 or P\<0.01P\<0.05 or P\<0.01P\<0.05 or P\<0.01P\<0.05 or P\<0.01P\<0.05 or P\<0.01P\<0.05 or P\<0.01P\<0.05 or P\<0.01P\<0.01P\<0.05P\<0.05P\<0.05
                  M\                                                                                                                                     PPT (5, 10 mg/kg) ig, 5 days                                                                                                                                                                                                                                                                                                                                                                        
                  26−28 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                  49                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B60]          KM mice\          --                                       Forced swimming test                                                        AGP (125, 250, 500 mg/kg) ig, 28 days                                 Distilled water for same volume   Swimming timeBLASUNhepatic glycogenSerum GSH-PxSerum SODSerum MDA                                                                                                                                                                                                                           P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01
                  F/M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                  20 ± 2 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                  80                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B47]          ICR mice\         --                                       Forced swimming test                                                        QOPs (225, 450, 900 mg/kg) ig, 30 days                                NS for same volume                Swimming timeSerum LDHBUNHepatic glycogenBLAskeletal muscle SODskeletal muscles GSH-Pxskeletal muscles MDANa+-K+-ATPaseCa2+-Mg2+- ATPaseSDHNRF-1TFAMmtDNA                                                                                                                                   P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  18--22 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                  240                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B81]          KM mice\          --                                       weight-loaded swimming (WLS) test                                           Ginseng (0.2 ml/10 g)\                                                Distilled water for same volume   Swimming timehypoxia tolerance timeBLAHepatic glycogenmuscle glycogenSerum BUN                                                                                                                                                                                                              P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01
                  F/M\                                                                                                                                   Red Ginseng (0.2 ml/10 g)\                                                                                                                                                                                                                                                                                                                                                                          
                  18--22 g\                                                                                                                              mild property ginseng (0.2 ml/10 g) ig, 14 days                                                                                                                                                                                                                                                                                                                                                     
                  70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B28]          mice\             --                                       weight-loaded swimming (WLS) test                                           Ginseng (1.25, 2.5, 5 mg/kg)\                                         NS for same volume                BLASerum BUNSerum SODSerum LDHHepatic glycogenmuscle glycogen                                                                                                                                                                                                                               P\<0.05P\<0.05P\>0.05P\>0.05P\<0.01P\<0.01
                  M\                                                                                                                                     Red Ginseng (1.25, 2.5, 5 mg/kg)                                                                                                                                                                                                                                                                                                                                                                    
                  18--22 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                  120                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B51]          ICR mice\         --                                       Forelimb Grip Strength/weight-loaded swimming (WLS) test                    CMG extract (5, 25 mg/kg) ig, 4 weeks                                 Distilled water for same volume   Forelimb grip strengthSwimming timeSerum LactateSerum NH3Serum CKSerum GLUSerum BUNHepatic glycogenmuscle glycogenSerum LDHorgan index                                                                                                                                                      P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\<0.01P\>0.05P\<0.01P\>0.05P\>0.05
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  NG\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                  24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B11]          ICR mice\         --                                       restraint stress/Overcoming electroshock/Cold swimming test/Rota-rod test   RG (50, 100, 200, 400 mg/kg) ig, 7 days                               NR                                Serum CORTBlood lactic acid                                                                                                                                                                                                                                                                 P\<0.05P\>0.05
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  17--20 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                  40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B33]          ICR mice\         --                                       aerobic running exercise                                                    RG(1 g/kg) ig, 2 weeks                                                Distilled water for same volume   1.body weightCarbohydrate OxidationFat OxidationSerum Free fatty acidSerum GlucoseSerumInsulinLiverglycogenGastrocnemius-white muscle glycogenGastrocnemius-red muscle glycogen                                                                                                             P\>0.05P\>0.05P\>0.05P\<0.05P\>0.05P\>0.05P\<0.05P\>0.05P\>0.05
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  NG\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                  43                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B63]          KM mice\          --                                       weight-loaded swimming (WLS) test and Rota-rod test                         BG(1.65, 3.30, 4.95 g/kg) ig, 2 weeks                                 Distilled water for same volume   body weightpole-climbing timeswimming timeliverglycogenblood lactic acidSerum LDH                                                                                                                                                                                                           P\>0.05P\<0.001P\<0.001P\<0.01P\<0.01P\<0.01
                  M\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                  18--22 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                  20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5-HT, 5-hydroxytryptamine; Ach, acetylcholine; BLA, Blood lactic acid; BUN, blood urea nitrogen; CK, creatine phosphokinase; CORT, corticosterone; DA, dopamine; GABA, gamma-aminobutyric acid; GLU, glucose; GSH-Px, glutathione peroxidase; LDH, lactic dehydrogenase; MDA, malondialdehyde; mtDNA, mitochondrial DNA; NRF-1, Nuclear respiratory factor 1; PTS, panaxtrol saponin; SDH, succinate dehydrogenase; SOD, superoxide dismutase; TG, triglyceride; TFAM, Mitochondrial transcription factor A; WGP, water-soluble ginseng polysaccharides; WGPA, ginseng pectin; WGPN, starch-like glucans.

###### 

Statement of the characteristics of *Panax ginseng* C. A. Mey and its compounds(b).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study    Herb source                Type of herbal or bioactive compound                                Purity         Approach to achieving                                                                      Quality control\                   Chemical analysis   Structure or Composition
                                                                                                                                                                                                                    (lot number)                                           
  -------- -------------------------- ------------------------------------------------------------------- -------------- ------------------------------------------------------------------------------------------ ---------------------------------- ------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B77]   *Panax ginseng* C.A. Mey   Ginseng proteins                                                    80%            not reported                                                                               Not reported                       included-UC         --

  [@B70]   *Panax ginseng* C.A. Mey   Ginseng polysaccharides                                             not reported   the School of Life Sciences, Northeast Normal University, China                            reported\                          included-HPLC       --
                                                                                                                                                                                                                    (20081001)                                             

  [@B71]   *Panax ginseng* C.A. Mey   Ginseng pectin polysaccharide                                       not reported   the School of Life Sciences, Northeast Normal University, China                            reported\                          included-HPLC       --
                                                                                                                                                                                                                    (20081001)                                             

  [@B65]   *Panax ginseng* C.A. Mey   PTS                                                                 not reported   Department of Pathophysiology, Basic Medical College of Jilin University, Jilin, China     not reported                       not included        --

  [@B76]   *Panax ginseng* C.A. Mey   Ginsenoside Rb1                                                     not reported   Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China                                 not reported                       included-HPLC       ![](fphar-11-01031-g011.jpg)

  [@B23]   *Panax ginseng* C.A. Mey   Ginsenoside\                                                        not reported   Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China                                 not reported                       included-HPLC       ![](fphar-11-01031-g012.jpg)
                                      Ginsenoside Rb1                                                                                                                                                                                                                      

  [@B23]   *Panax ginseng* C.A. Mey   Ginsenoside\                                                        not reported   Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China                                 not reported                       included-HPLC       ![](fphar-11-01031-g013.jpg)
                                      Ginsenoside Re                                                                                                                                                                                                                       

  [@B50]   *Panax ginseng C.A. Mey*   Ginsenoside Rg1                                                     98.59%         Dingguo Biotechnology Co., Ltd., China                                                     not reported                       included-HPLC       ![](fphar-11-01031-g014.jpg)

  [@B24]   *Panax ginseng* C.A. Mey   Ginsenoside Rb1\                                                    not reported   Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China                                 not reported                       included-HPLC       ![](fphar-11-01031-g015.jpg) ![](fphar-11-01031-g016.jpg)
                                      Ginsenoside Rg1                                                                                                                                                                                                                      

  [@B72]   *Panax ginseng* C.A. Mey   Ginsenoside Rg1                                                     98%            Department of Organic Chemistry, Basic Medical College of Jilin University, Jilin, China   not reported                       included-HPLC       ![](fphar-11-01031-g017.jpg)

  [@B79]   *Panax ginseng* C.A. Mey   ginsenoside                                                         not reported   not reported                                                                               not reported                       not included        

  [@B49]   *Panax ginseng* C.A. Mey   Ginsenoside                                                         \> 80%         Xi\'an Ruiying Biotechnology Co., Ltd., Xi\'an, China                                      reported (RYRS20140325)            not included        

  [@B21]   *Panax ginseng* C.A. Mey   Ginsenoside Re                                                      not reported   Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China                                 Reported-according to (07120623)   included-HPLC       ![](fphar-11-01031-g018.jpg)

  [@B25]   *Panax ginseng* C.A. Mey   Ginsenoside Rg1                                                     not reported   Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China                                 reported (07120624)                included-HPLC       ![](fphar-11-01031-g019.jpg)

  [@B56]   *Panax ginseng* C.A. Mey   Ginsenosides                                                        not reported   Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China                                 not reported                       included-HPLC       --

  [@B9]    *Panax ginseng* C.A. Mey   Ginsenosides                                                        not reported   Jilin Yawei Pharmaceutical Co., Ltd., Jilin, China                                         Reported\                          included-HPLC       --
                                                                                                                                                                                                                    (94032019)                                             

  [@B55]   *Panax ginseng* C.A. Mey   Ginsenosides\                                                       not reported   Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China                                 not reported                       included-HPLC       ![](fphar-11-01031-g020.jpg)
                                      Ginsenoside Rg1                                                                                                                                                                                                                      

  [@B48]   *Panax ginseng* C.A. Mey   Pseudo- ginsenoside GQ Rg                                           98.7%          Institute of Regenerative Medicine, Jilin University, Jilin, China                         not reported                       not included        --

  [@B25]   *Panax ginseng* C.A. Mey   Ginsenoside Rb1\                                                    not reported   Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China                                 not reported                       included-HPLC       ![](fphar-11-01031-g021.jpg) ![](fphar-11-01031-g022.jpg)
                                      Ginsenoside Re                                                                                                                                                                                                                       

  [@B57]   *Panax ginseng* C.A. Mey   Ginsenoside Rb1                                                     not reported   Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China                                 not reported                       included-HPLC       ![](fphar-11-01031-g023.jpg)

  [@B5]    *Panax ginseng* C.A. Mey   ginseng oligopeptides (GOP)                                         95.42%         Jilin Taigu Biological Engineering Co., Ltd., Jilin, China                                 not reported                       included-HPLC       --

  [@B54]   *Panax ginseng* C.A. Mey   20(S)-Protopanaxadiol(PPD)\                                         ≥98%           the College of Pharmacy, Kyung HeeUniversity, Geumsan, Korea                               reported (KHUP201409201)           Included-HPLC       ![](fphar-11-01031-g024.jpg) ![](fphar-11-01031-g025.jpg)
                                      20(S)-Protopanaxatriol(PPT)                                                                                                                                                                                                          

  [@B60]   Panaxquinquefolium         American ginseng proteins (AGP)                                     80%            Agilent Technologies, USA                                                                  not reported                       included-HPLC       --

  [@B47]   Panaxquinquefolium         small-molecule oligopeptides isolated from American ginseng(QOPs)   96.46%         SinoMed Peptide Valley Bioengineering Co., Ltd., China                                     reported\                          included-HPLC       --
                                                                                                                                                                                                                    (CN105154509A)                                         

  [@B81]   Red ginseng                Ginseng\                                                            not reported   not reported                                                                               not reported                       not included        Red GinsengContain 4.015% ginsenosides (Rg1 0.262%, Re 0.145%, Rf 0.151%, Rh1 0.284%, Rg2 0.402%, Rb1 0.394%, Rc 0.318%, Rb2 0.247%, Rb3 0.465%, Rd 0.437%, Rg3 0.412%, Rk1 0.194%, Rg5 0.304%) HPLC data from [@B40]
                                      Red Ginseng\                                                                                                                                                                                                                         
                                      mild property ginseng                                                                                                                                                                                                                

  [@B28]   *Panax ginseng* C.A. Mey   Ginseng\                                                            not reported   not reported                                                                               not reported                       not included        Red GinsengContain 4.015% ginsenosides (Rg1 0.262%, Re 0.145%, Rf 0.151%, Rh1 0.284%, Rg2 0.402%, Rb1 0.394%, Rc 0.318%, Rb2 0.247%, Rb3 0.465%, Rd 0.437%, Rg3 0.412%, Rk1 0.194%, Rg5 0.304%) HPLC data from [@B40]
                                      Red Ginseng                                                                                                                                                                                                                          

  [@B51]   *Panax ginseng* C.A. Mey   Changbai Mountain Ginseng(CMG)                                      not reported   not reported                                                                               not reported                       included-HPLC       Contain 11.5% ginsenosides (Ra1 0.46%, Ra2 0.69%, Rb1 0.22%, Rb2 0.94%, Rb3 1.22%, Rc 0.33%, Rd 1.54%, Re 0.11%, Rf 1.14%, Rg1 0.2%, Ro 1.19%, 20-glc-G-Rf 1.60%, R1 0.71%, R2 1.15%) HPLC data from Wang et al. 2017

  [@B11]   Red ginseng                Ren Ginseng                                                         not reported   Korea Ginseng Corp., Seoul, Korea                                                          not reported                       included-HPLC       Contain 4.015% ginsenosides (Rg1 0.262%, Re 0.145%, Rf 0.151%, Rh1 0.284%, Rg2 0.402%, Rb1 0.394%, Rc 0.318%, Rb2 0.247%, Rb3 0.465%, Rd 0.437%, Rg3 0.412%, Rk1 0.194%, Rg5 0.304%) HPLC data from [@B40]

  [@B33]   Red ginseng                Ren Ginseng                                                         not reported   Korea Ginseng Corp., Seoul, Korea                                                          not reported                       included-HPLC       Contain 1.964% ginsenosides(Rg1 0.071%, Re 0.093%, Rf 0.121%, Rf1 0.078%, Rg2(s) 0.192%, Rg2 0.129%, Rb1 0.462%, Rc 0.241%, Rb2 0.183%, Rd 0.089%, Rg3(s) 0.214%, Rg3 0.091%) HPLC data from [@B33]

  [@B63]   Black ginseng              black Ginseng                                                       not reported   HunchunXuzhu Trading Co., Ltd., Jilin, China                                               not reported                       not included        Contain 3.341% ginsenosides (Rg1 0.232%, Re 0.186%, Rf 0.158%, Rb1 0.184%, Rc 0.145%, Rb2 0.174%, Rd 0.169%, Rg6 0.138%, F4 0.127%, Rk3 0.162%, Rh4 0.102%, 20(S)-Rg3 0.173%, 20(R)-Rg3 0.121%, 20(S)-Rs3 0.146%, 20(R)-Rs3 0.213%, Rk1 0.178%, Rg5 0.321%, Rs5 0.225%, Rs4 0.187%) HPLC data from [@B67]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HPLC, high-performance liquid chromatography; PGC, ginseng and its compounds.

Study Quality {#s3_3}
-------------

### Randomized Clinical Trials {#s3_3_1}

[**Table 5**](#T5){ref-type="table"} illustrates the methodological quality of 8 RCTs based on the Cochrane Collaboration\'s tool. All of them were ranged from 4 to 7 points. All included studies reported the method of random sequences generation, the criteria of a double-blind study design, and taking the complete outcome data into account. Three studies ([@B31]; [@B34]; [@B44]) reported using allocation concealment. Two studies ([@B31]; [@B44]) applied blinding specifically during outcome measure assessment. The protocols of 3 studies ([@B34]; [@B41]; [@B44]) were registered in the Clinical Trial Registry. In other bias, all eight studies were supported by nonprofit institutions and accounted for baseline comparability, but no study provided sample size estimation information.

###### 

The methodological quality of included randomized control trials.

  included studies   A    B    C    D    E    F    G    Total score
  ------------------ ---- ---- ---- ---- ---- ---- ---- -------------
  [@B15]             \+   ?    \+   ?    \+   ?    \+   4+
  [@B17]             \+   ?    \+   ?    \+   ?    \+   4+
  [@B16]             \+   ?    \+   ?    \+   ?    \+   4+
  [@B31]             \+   \+   \+   \+   \+   ?    \+   6+
  [@B34]             \+   \+   \+   ?    \+   \+   \+   6+
  [@B41]             \+   ?    \+   ?    \+   \+   \+   5+
  [@B44]             \+   \+   \+   \+   \+   \+   \+   7+
  [@B27]             \+   ?    \+   ?    \+   ?    \+   4+

A, random sequence generation; B, allocation concealment; C, blinding of participants and personnel; D, blinding of outcome assessment; E, incomplete outcome data; F, selective reporting; G, other sources of bias.

### Animal Studies {#s3_3_2}

The quality scores of studies included varied from 4 to 7 out of 10 points with the average of 5.73. Of which, 4 studies ([@B21]; [@B72]; [@B50]; [@B79]) got 4 points; 6 studies ([@B48]; [@B76]; [@B9]; [@B77]; [@B49]; [@B63]) got 5 points; 13 studies ([@B20]; [@B21]; [@B23]; [@B24]; [@B25]; [@B56]; [@B57]; [@B11]; [@B28]; [@B65]; [@B71]; [@B81]; [@B82]) got 6 points; and 6 studies ([@B33]; [@B60]; [@B54]; [@B5]; [@B51]; [@B14]) got 7 points. All the included records described appropriate animal models (aged or female involved) and used an anesthetic without significant intrinsic neuroprotective activity. However, no study reported blinded induction of model, blinding their assessment of outcome, and a sample size calculation. Twenty-nine studies ([@B20]; [@B21]; [@B22]; [@B48]; [@B55]; [@B23]; [@B24]; [@B25]; [@B56]; [@B57]; [@B76]; [@B9]; [@B11]; [@B28]; [@B77]; [@B65]; [@B33]; [@B60]; [@B71]; [@B81]; [@B49]; [@B54]; [@B72]; [@B5]; [@B63]; [@B79]; [@B51]; [@B82]; [@B14]) were peer-reviewed publications. Twenty-seven studies ([@B20]; [@B21]; [@B22]; [@B48]; [@B55]; [@B23]; [@B24]; [@B25]; [@B56]; [@B57]; [@B76]; [@B9]; [@B28]; [@B77]; [@B65]; [@B33]; [@B60]; [@B81]; [@B49]; [@B54]; [@B72]; [@B5]; [@B50]; [@B63]; [@B79]; [@B51]; [@B14]) allocated randomly to treatment group and control group. Twenty-four studies ([@B20]; [@B21]; [@B55]; [@B23]; [@B24]; [@B25]; [@B56]; [@B57]; [@B76]; [@B9]; [@B28]; [@B11]; [@B65]; [@B33]; [@B60]; [@B71]; [@B81]; [@B54]; [@B5]; [@B50]; [@B63]; [@B51]; [@B82]; [@B14]) described control of temperature. Twenty-four studies ([@B20]; [@B21]; [@B48]; [@B55]; [@B23]; [@B24]; [@B25]; [@B56]; [@B57]; [@B11]; [@B28]; [@B77]; [@B65]; [@B33]; [@B60]; [@B71]; [@B81]; [@B49]; [@B54]; [@B5]; [@B50]; [@B51]; [@B82]; [@B14]) declared no potential conflict of interests, and 9 studies ([@B11]; [@B33]; [@B60]; [@B71]; [@B54]; [@B5]; [@B51]; [@B82]; [@B14]) reported compliance with animal welfare regulations. The methodological quality is concluded in [**Table 6**](#T6){ref-type="table"}.

###### 

Risk of bias of the included animal studies.

  Study    A    B    C    D   E   F    G    H   I    J    Total
  -------- ---- ---- ---- --- --- ---- ---- --- ---- ---- -------
  [@B77]   \+   ?    \+   ?   ?   \+   \+   ?   ?    \+   5+
  [@B70]   \+   \+   ?    ?   ?   \+   \+   ?   \+   \+   6+
  [@B71]   \+   \+   ?    ?   ?   \+   \+   ?   \+   \+   6+
  [@B65]   \+   \+   \+   ?   ?   \+   \+   ?   ?    \+   6+
  [@B76]   \+   \+   \+   ?   ?   \+   \+   ?   ?    ?    5+
  [@B23]   \+   \+   \+   ?   ?   \+   \+   ?   ?    \+   6+
  [@B20]   \+   \+   \+   ?   ?   \+   \+   ?   ?    \+   6+
  [@B50]   --   \+   \+   ?   ?   \+   \+   ?   ?    \+   4+
  [@B24]   \+   \+   \+   ?   ?   \+   \+   ?   ?    \+   6+
  [@B72]   \+   ?    \+   ?   ?   \+   \+   ?   ?    ?    4+
  [@B79]   \+   ?    \+   ?   ?   \+   \+   ?   ?    ?    4+
  [@B49]   \+   ?    \+   ?   ?   \+   \+   ?   ?    \+   5+
  [@B24]   \+   ?    \+   ?   ?   \+   \+   ?   ?    ?    4+
  [@B25]   \+   \+   \+   ?   ?   \+   \+   ?   ?    \+   6+
  [@B56]   \+   \+   \+   ?   ?   \+   \+   ?   ?    \+   6+
  [@B56]   \+   \+   \+   ?   ?   \+   \+   ?   ?    ?    5+
  [@B55]   \+   \+   \+   ?   ?   \+   \+   ?   ?    \+   6+
  [@B48]   \+   ?    \+   ?   ?   \+   \+   ?   ?    \+   5+
  [@B22]   \+   \+   \+   ?   ?   \+   \+   ?   ?    \+   6+
  [@B57]   \+   \+   \+   ?   ?   \+   \+   ?   ?    \+   6+
  [@B5]    \+   \+   \+   ?   ?   \+   \+   ?   \+   \+   7+
  [@B54]   \+   \+   \+   ?   ?   \+   \+   ?   \+   \+   7+
  [@B60]   \+   \+   \+   ?   ?   \+   \+   ?   \+   \+   7+
  [@B47]   \+   \+   \+   ?   ?   \+   \+   ?   \+   \+   7+
  [@B81]   \+   \+   \+   ?   ?   \+   \+   ?   ?    \+   6+
  [@B28]   \+   \+   \+   ?   ?   \+   \+   ?   ?    \+   6+
  [@B51]   \+   \+   \+   ?   ?   \+   \+   ?   \+   \+   7+
  [@B11]   \+   \+   ?    ?   ?   \+   \+   ?   \+   \+   6+
  [@B33]   \+   \+   \+   ?   ?   \+   \+   ?   \+   \+   7+
  [@B63]   \+   \+   \+   ?   ?   \+   \+   ?   ?    ?    5+

Studies fulfilling the criteria of the following: (A) peer reviewed publication; (B) control of temperature; (C) random allocation to treatment or control; (D) blinded induction of model; (E) blinded assessment of outcome; (F) use of anesthetic without significant intrinsic neuroprotective activity; (G) animal model (aged or female involved); (H) sample size calculation; (I) compliance with animal welfare regulations; (J) statement of potential conflict of interests.

Effectiveness {#s3_4}
-------------

### Randomized Control Trials {#s3_4_1}

Five studies ([@B27]; [@B31]; [@B34]; [@B41]; [@B44]) described the treatment of CFS patients. These studies utilized different scales of fatigue to measure therapeutic effect. Therefore, the meta-analysis was not conducted because of different evaluation criteria. All studies showed significant difference in their respective fatigue scales for PGC relative to placebo. Three studies ([@B27]; [@B31]; [@B41]) reported clinical effect, which according to different self-reported fatigue scales. Meta-analysis of 3 studies ([@B27]; [@B31]; [@B41]) found significant difference in clinical effect for PGC relative to placebo (nT/nC =181/133, OR=1.31, 95% CI: 1.17 to 1.46, P \< 0 00001; heterogeneity χ^2^ = 1.94, df = 2 (P=0.38), I^2^ = 0%) ([**Figure 2A**](#f2){ref-type="fig"}). Meta-analysis of 5 studies ([@B27]; [@B31]; [@B34]; [@B41]; [@B44]) showed there was no significant difference in the frequency of adverse events between the groups (nT/nC =293/297, OR=1.09, 95% CI: 0.48 to 2.46, P=0.83, heterogeneity χ^2^ = 6.99, df = 4 (P=0.14), I^2^ = 0%) ([**Figure 2B**](#f2){ref-type="fig"}).

![**(A)** Clinical effect of *Panax ginseng* C. A. Mey and its compounds versus Placebo. **(B)** Adverse events of *Panax ginseng* C. A. Mey and its compounds versus Placebo. **(C)** Heart rate recovery of *Panax ginseng* C. A. Mey and its compounds versus Placebo.](fphar-11-01031-g002){#f2}

Three studies ([@B15]; [@B17]; [@B16]) described the effect of PGC on physical performance recovery of healthy adults after exercise fatigue. Meta-analysis of 3 studies ([@B15]; [@B17]; [@B16]) found significant difference in heart rate recovery after exercise compared the PGC with placebo (nT/nC = 35/30; FE = −5.73; 95% CI, −9.22 to −2.55; *P* = 0.001; heterogeneity χ^2^ = 3.80, df = 2 (*P* = 0.15), *I* ^2^ = 47%) ([**Figure 2C**](#f2){ref-type="fig"}).

### Animal Studies {#s3_4_2}

#### The Swimming Time {#s3_4_2_1}

Meta-analysis of 8 studies ([@B48]; [@B77]; [@B81]; [@B49]; [@B72]; [@B63]; [@B79]; [@B51]) showed PGC significantly increased the swimming time in WLST compared with control (n = 98, SMD =2.21, 95% CI: 1.83 to 2.59, P \< 0 00001; heterogeneity: χ^2^ = 18.96, df = 7 (P =0.008), I^2^ = 63%). Owing to obvious heterogeneity, we used sensitivity analyses and removed one study ([@B48]) that trained the mice before the swimming test. Meta-analysis of 7 studies showed a significant effect of PGC in increasing the swimming time in WLST compared with control (n = 78, SMD =2.60, 95% CI: 2.14 to 3.06, P \< 0 00001; heterogeneity: χ^2^ = 9.75, df = 6 (P =0.14), I^2^ = 38%) ([**Figure 3A**](#f3){ref-type="fig"}). Five studies ([@B11]; [@B65]; [@B60]; [@B5]; [@B14]) found that PGC was more effective in increasing the swimming time in FST than that of control (n = 67, SMD =2.78, 95% CI: 2.24 to 3.32, P \< 0 00001; heterogeneity: χ^2^ = 41.15, df = 4 (P \< 0 00001), I^2^ = 90%). Two studies ([@B11]; [@B65]) may be considered as the probable source of the heterogeneity, in which 1 study ([@B65]) utilized rats as experimental subjects and one study ([@B11]) utilized crude products of PG. After getting rid of these 2 studies, there was showing that PGC increasing the swimming time in FST (n = 47, SMD =4.71, 95% CI: 3.88 to 5.54, P \< 0 00001; heterogeneity: χ^2^ = 2.12, df = 2 (P =0.35), I^2^ = 6%) ([**Figure 3B**](#f3){ref-type="fig"}).

![**(A)** Forced swimming test of *Panax ginseng* C. A. Mey and its compounds versus Control. **(B)** Weight-loaded swimming test of *Panax ginseng* C. A. Mey and its compounds versus Control.](fphar-11-01031-g003){#f3}

#### Serum Biochemical Parameters {#s3_4_2_2}

Meta-analysis of 3 studies ([@B60]; [@B71]; [@B82]) showed PGC was significant for increasing level of GSH-Px compared with control (n = 47, SMD =2.16, 95% CI: 1.49 to 3.02, P \< 0 00001; heterogeneity: χ^2^ = 46.87, df = 2 (P \< 0 00001), I^2^ = 96%). After sensitivity analyses, we removed 1 study ([@B60]) that utilized ginseng protein as intervention. Meta-analysis of the rest of 2 studies found that PGC significantly increased the level of GSH-Px compared with control (n = 16, SMD =1.42, 95% CI: 0.61 to 2.22, P =0.0005; heterogeneity: χ^2^ = 0.37, df = 1 (P =0.54), I^2^ = 0%) ([**Figure 4A**](#f4){ref-type="fig"}). Compared with controls, meta-analysis of 5 studies ([@B65]; [@B71]; [@B72]; [@B54]; [@B51]) showed that PGC significantly increased level of GLU (n = 41, SMD =1.69, 95% CI: 1.16 to 2.23, P \< 000001; heterogeneity: χ^2^ = 4.65, df = 4 (P =0.32), I^2^ = 14%) ([**Figure 4B**](#f4){ref-type="fig"}); 11 studies ([@B48]; [@B28]; [@B77]; [@B65]; [@B60]; [@B81]; [@B49]; [@B72]; [@B5]; [@B79]; [@B51]; [@B14]) for reducing level of BUN (n = 160, SMD = −1.05; 95% CI, −1.29 to −0.80; *P* \< 000001; heterogeneity: χ^2^ = 21.75, df = 10 (*P* \< 0 00001), I^2^ = 49%) ([**Figure 4C**](#f4){ref-type="fig"}); 15 studies ([@B48]; [@B11]; [@B28]; [@B77]; [@B65]; [@B60]; [@B81]; [@B49]; [@B54]; [@B72]; [@B5]; [@B50]; [@B63]; [@B79]; [@B14]) for reducing level of BLA (n = 186; SMD = −1.25; 95% CI, −1.48 to −1.02; P \< 000001; heterogeneity: χ^2^ = 24.26; df = 14 (P =0.04); I^2^ = 42%) ([**Figure 4D**](#f4){ref-type="fig"}); four studies ([@B49]; [@B79]; [@B51]; [@B82]) for reducing level of CK (n = 44; SMD = −2.48; 95% CI, −3.07 to −1.89; P \< 000001; heterogeneity: χ^2^ = 4.22, df = 3 (P=0.24), I^2^ = 29%) ([**Figure 5A**](#f5){ref-type="fig"}); five studies ([@B22]; [@B56]; [@B60]; [@B71]; [@B82]) for reducing level of MDA (n = 44; SMD = −2.86; 95% CI, −3.42 to −2.30; *P* \< 0 00001; heterogeneity, χ^2^ = 6.42, df = 3 (*P* = 0.17), I^2^ = 38%) ([**Figure 5B**](#f5){ref-type="fig"}); five studies ([@B22]; [@B56]; [@B60]; [@B71]; [@B82]) for increasing level of SOD (n = 56; SMD = 2.35; 95% CI, 1.84 to 2.86, *P* \< 000001; heterogeneity: χ^2^ = 4.86, df = 4 (P =0.30), I^2^ = 18%) ([**Figure 5C**](#f5){ref-type="fig"}); four studies ([@B71]; [@B54]; [@B51]; [@B82]) for reducing level of LDH (n = 29; SMD = −2.28; 95% CI, −3.00 to −1.55, *P* \< 0 00001; heterogeneity: χ^2^ = 3.76, df = 3 (*P* = 0.29), I^2^ = 20%) ([**Figure 5D**](#f5){ref-type="fig"}). Six studies ([@B48]; [@B49]; [@B5]; [@B63]; [@B79]; [@B14]) found that PGC was more effective for increasing activity of LDH than that of control (P\< 0.05). No meta-analysis was carried out because of high heterogeneity.

![**(A)** Level of glutathione peroxidase in serum of *Panax ginseng* C. A. Mey and its compounds versus Control. **(B)** Level of glucose in serum of *Panax ginseng* C. A. Mey and its compounds versus Control. **(C)** Level of blood urea nitrogen in serum of *Panax ginseng* C. A. Mey and its compounds versus Control. **(D)** Level of blood lactate in serum of *Panax ginseng* C. A. Mey and its compounds versus Control.](fphar-11-01031-g004){#f4}

![**(A)** Level of creatine kinase in serum of *Panax ginseng* C. A. Mey and its compounds versus Control. **(B)** Level of malondialdehyde in serum of *Panax ginseng* C. A. Mey and its compounds versus Control. **(C)** Level of superoxide dismutase in serum of *Panax ginseng* C. A. Mey and its compounds versus Control. **(D)** Level of lactic dehydrogenase in serum of *Panax ginseng* C. A. Mey and its compounds versus Control.](fphar-11-01031-g005){#f5}

#### Skeletal Muscle Biochemical Parameters: {#s3_4_2_3}

Meta- analysis of 6 studies ([@B48]; [@B24]; [@B28]; [@B81]; [@B72]; [@B51]) showed a significant effect of PGC for increasing level of muscle glycogen compared with control (n = 68, SMD =0.80, 95% CI: 0.43 to 1.17, P \< 000001; heterogeneity: χ^2^ = 17.10, df = 5 (P =0.004), I^2^ = 71%). After removing 1 studies ([@B24]) that utilized rats as experimental subjects, meta- analysis of 5 studies ([@B48]; [@B28]; [@B81]; [@B72]; [@B51]) showed similar results (n = 58, SMD =0.63, 95% CI: 0.25 to 1.01, P =0.001; heterogeneity: χ^2^ = 6.14, df = 4 (P =0.19), I^2^ = 35%) ([**Figure 6A**](#f6){ref-type="fig"}). Compared with control, meta-analysis of 9 studies ([@B22]; [@B23]; [@B24]; [@B56]; [@B57]; [@B76]; [@B5]; [@B50]; [@B14]) showed that PGC significantly improved activity of SOD (n = 97, SMD =2.61, 95% CI: 2.19 to 3.03, P \< 0 00001; heterogeneity: χ^2^ = 23.71, df = 8 (P =0.003), I^2^ = 66%). Sensitivity analyses were conducted to explore potential sources of heterogeneity. After removing 1 trial ([@B57]) that utilized crude products of PG, meta-analysis of 8 studies ([@B22]; [@B23]; [@B24]; [@B56]; [@B76]; [@B5]; [@B50]; [@B14]) showed that PGC was still superior to the control (n = 87, SMD =2.96, 95% CI: 2.49 to 3.42, P \< 000001; heterogeneity: χ^2^ = 12.32, df = 7 (P =0.09), I^2^ = 43%) ([**Figure 6B**](#f6){ref-type="fig"}). Compared with control group, meta-analysis of 2 studies ([@B50]; [@B5]) showed that PGC had significant effect to increase activity of CAT (n = 25, SMD =1.90, 95% CI: 1.21 to 2.59, P \< 0 00001; heterogeneity: χ^2^ = 1.05, df = 41 (P =0.31), I^2^ = 5%) ([**Figure 6C**](#f6){ref-type="fig"}); 2 studies ([@B50]; [@B14]) for improving activity of GSH-Px (n = 22, SMD =2.01, 95% CI: 1.26 to 2.77, P \< 0 00001; heterogeneity: χ^2^ = 0.47, df = 1 (P =0.49), I^2^ = 0%) ([**Figure 6D**](#f6){ref-type="fig"}). The level of MDA was reported in 9 studies ([@B22]; [@B24]; [@B25]; [@B56]; [@B57]; [@B76]; [@B5]; [@B50]; [@B14]). There was significant decreasing in the level of MDA compared PGC with control (P \< 0.05). No meta-analysis was carried out because of high heterogeneity.

![**(A)** Level of glycogen in muscle of *Panax ginseng* C. A. Mey and its compounds versus Control. **(B)** Activity of superoxide dismutase in muscle of *Panax ginseng* C. A. Mey and its compounds versus Control. **(C)** Activity of catalase in muscle of Panax ginseng C. A. Mey and its compounds versus Control. **(D)** Activity of glutathione peroxidase in muscle of *Panax ginseng* C. A. Mey and its compounds versus Control.](fphar-11-01031-g006){#f6}

#### Liver Biochemical Parameters {#s3_4_2_4}

Meta-analysis of 11 studies ([@B28]; [@B77]; [@B81]; [@B60]; [@B49]; [@B72]; [@B63]; [@B79]; [@B5]; [@B51]; [@B14]) showed that PGC had significant effects for increasing level of hepatic glycogen compared with control (n = 135, SMD =2.19, 95% CI: 1.86 to 2.52, P \< 000001; heterogeneity: χ^2^ = 58.77, df = 10 (P \< 0 00001), I^2^ = 83%).Owing to obvious heterogeneity, we conducted subgroup analysis. These studies were divided into 4 subgroups according to different experiment interventions. Meta-analysis showed that there was significant difference in the level of glycogen between PGC and control in all subgroups, including ginseng ([@B28]; [@B81]; [@B63]; [@B51]), Ginsenosides ([@B49]; [@B72]; [@B79]), ginseng protein ([@B77]; [@B60]), and ginseng oligopeptides ([@B5]; [@B14]) groups ([**Figure 7A**](#f7){ref-type="fig"}). Meta-analysis of 4 studies ([@B22]; [@B56]; [@B49]; [@B79]) showed that PGC significantly decreased level of MDA compared with control (n = 50; SMD = −2.01; 95% CI, −2.50 to −1.51; *P* \< 000001; heterogeneity: χ^2^ = 1.69, df = 3 (*P* = 0.64), I^2^ = 0%) ([**Figure 7B**](#f7){ref-type="fig"}). Meta-analysis of two studies ([@B49]; [@B79]) showed no significant difference in activity of GSH-Px between PGC and control (n = 30; SMD = 1.81; 95% CI, −7.98 to 11.60, *P* =0.72; heterogeneity: χ^2^ = 0.00, df = 1 (P =1.00), I^2^ = 0%) ([**Figure 7C**](#f7){ref-type="fig"}). Activity of SOD was reported in four studies ([@B22]; [@B56]; [@B49]; [@B79]). Two studies ([@B22]; [@B56]) showed significant difference (*P* \< 0.05) for increasing activity of SOD compared PGC with control, whereas 2 studies ([@B49]; [@B79]) showed contradictory results (*P* \> 0.05).

![**(A)** Level of glycogen in Liver of *Panax ginseng* C. A. Mey and its compounds versus Control. **(B)** Activity of malondialdehyde in Liver of *Panax ginseng* C. A. Mey and its compounds versus Control. **(C)** Activity of glutathione peroxidase in Liver of *Panax ginseng* C. A. Mey and its compounds versus Control.](fphar-11-01031-g007){#f7}

#### Brain Tissue Biochemical Parameters {#s3_4_2_5}

Meta-analysis of 5 studies ([@B20]; [@B21]; [@B55]; [@B23]; [@B9]) showed PGC was significant for reducing level of GABA (n = 55; SMD = −4.45; 95% CI, −5.24 to −3.66; *P* \< 0.00001; heterogeneity: χ^2^ = 17.97, df = 4 (P = 0.001), I^2^ = 78%) and level of 5-HT (n = 55; SMD = −1.19; 95% CI, −1.63 to −0.76; *P* \< 0 00001; heterogeneity: χ^2^ = 15.52, df = 4 (P =0.004), I^2^ = 74%) compared with control. One study ([@B9]) that utilize chloral hydrate to anesthetize rats may be considered as the probable source of the heterogeneity. After getting rid of this study, there was showing that PGC better reduce the level of GABA (n = 40; SMD = −6.12; 95% CI, −7.27 to −4.96; *P* \< 000001; heterogeneity: χ^2^ = 3.10, df = 3 (*P* = 0.38), I^2^ = 3%) ([**Figure 8A**](#f8){ref-type="fig"}) and 5-HT (n = 40; SMD = −1.77; 95% CI, −2.31 to −1.23; *P* \< 0 00001; heterogeneity: χ^2^ = 3.62, df = 3 (*P* = 0.31), *I* ^2^ = 17%) ([**Figure 8B**](#f8){ref-type="fig"}). Meta-analysis of five studies ([@B20]; [@B21]; [@B55]; [@B23]; [@B9]) found significant difference for increasing level of Ach between PGC and control groups (n = 55; SMD = 1.86; 95% CI, 1.38 to 2.23; *P* \< 0 00001; heterogeneity: χ^2^ = 9.70, df = 4 (P =0.05), I^2^ = 59%). After removing one study ([@B20]), meta-analysis of four studies ([@B21]; [@B55]; [@B23]; [@B9]) showed similar results (n = 45; SMD = 1.66; 95% CI, 1.16 to 2.16, *P* \< 000001; heterogeneity: χ^2^ = 3.21, df = 3 (*P* = 0.36), I^2^ = 6%) ([**Figure 8C**](#f8){ref-type="fig"}). Meta-analysis of five studies ([@B20]; [@B21]; [@B55]; [@B23]; [@B9]) showed a significant increase in level of DA compared PGC with control (n = 55; SMD =1.76,; 95% CI, 1.26 to 2.22; *P* \< 000001; heterogeneity: χ^2^ = 6.85, df = 4 (P = 0.14), I^2^ = 42%) ([**Figure 8D**](#f8){ref-type="fig"}).

![**(A)** Level of gamma-aminobutyric acid in brain tissue of *Panax ginseng* C. A. Mey and its compounds versus Control. **(B)** Level of 5-hydroxytryptamine in brain tissue of *Panax ginseng* C. A. Mey and its compounds versus Control. **(C)** Level of acetylcholine in brain tissue of *Panax ginseng* C. A. Mey and its compounds versus Control. **(D)** Level of dopamine in brain tissue of *Panax ginseng* C. A. Mey and its compounds versus Control.](fphar-11-01031-g008){#f8}

#### Animal Body Weight: {#s3_4_2_6}

Meta-analysis of 7 studies ([@B48]; [@B77]; [@B65]; [@B33]; [@B5]; [@B50]; [@B63]) showed there was no significant difference in body weight between PGC and control groups (n = 96; SMD =0.07; 95% CI: −0.21 to 0.36; *P* = 0.62; heterogeneity: χ^2^ = 8.87, df = 6 (P = 0.18), I^2^ = 32%) ([**Figure 9A**](#f9){ref-type="fig"}).

![**(A)** Body weight of *Panax ginseng* C. A. Mey and its compounds versus Control. **(B)** Funnel plots of blood urea nitrogen. **(C)** Funnel plots of blood lactate.](fphar-11-01031-g009){#f9}

Publication Bias {#s3_5}
----------------

Funnel plots were conducted for two outcomes ([**Figures 9B, C**](#f9){ref-type="fig"}). The results showed symmetrical distribution for the outcomes of BUN levels (Egger\'s test t = −1.05; 95% CI, −6.93 to 2.50; *P* = 0.320), which did not suggest an obvious publication bias. However, there was a significant bias in the BLA levels with Egger\'s test (*t* = −3.47; 95% CI, −5.14 to −1.19; *P* =0.004). Because the number of studies in the remaining outcomes was limited (n \< 10), funnel plot and Egger\'s test were not appropriate.

Possible Mechanisms {#s3_6}
-------------------

PGC improved activity of GSH-Px, CAT, and SOD, scavenged free radicals and their metabolites, reduced the excessive ROS, and decreased levels of MDA, CK, and LDH. PGC decreased nitric oxide synthase (NOS), reduced toxic oxidant peroxynitrite, and prevented mitochondrial dysfunction and lipid peroxidation. PGC may enhance fat mobilization and promote gluconeogenesis, increase the delivery of glucose, and maintain blood glucose level. PGC increased the LDH activity and the hepatic glycogen levels, and retarded the accumulation of BUN and BLA. PGC improved succinate dehydrogenase (SDH), Na^+^-K^+^-ATPase, and Ca^2+^Mg^2+^-ATPase activities, enhanced mitochondrial function, and produced more adenosine triphosphate (ATP). PGC attenuated MPP^+^-induced MPTP-induced and apoptosis. PGC increased Ach and DA levels, and decreased GABA and 5-HT levels in brain tissue ([**Figure 10**](#f10){ref-type="fig"}).

![Possible mechanisms of *Panax ginseng* C. A. Mey and its compounds anti-fatigue.](fphar-11-01031-g010){#f10}

Discussion {#s4}
==========

Summary of Evidence {#s4_1}
-------------------

This is the clinical and preclinical systematic review to evaluate the efficacy and safety of PGC for fatigue. Eight RCTs with 678 participants and 30 studies with 2249 animals were selected. The quality of RCTs included was high, and animal studies were generally moderate. The findings of RCTs demonstrated that PGC was superior to placebo according to their respective fatigue scales, heart rate recovery, and clinical effect. There were a similar number of adverse effects between PGC and placebo group. The evidence available from animal studies showed that PGC could preserve physical function after exercise, mainly through antioxidant, regulating carbohydrate metabolism, delaying the accumulation of metabolites, promoting mitochondrial function, neuroprotection, antiapoptosis, and regulating neurotransmitter disorder in central nervous system.

Limitations {#s4_2}
-----------

Some methodological flaws existed in the primary RCTs. First of all, 3 studies used allocation concealment ([@B31]; [@B34]; [@B44]). Trials with unreported or inadequate allocation concealment could be exaggerated an average 18% beneficial effect of interventions ([@B32]). Second, non-blinding of outcome assessment may lead to systemic errors. In previous reviews, non-blinding of outcome assessment can lead to an overestimation of treatment effect by 27% to 68%, depending on different outcome types, i.e., binary outcome, measurement scale outcome, and time-to-event outcome. However, in RCTs, blinded outcome assessment was commonly poor reported and used. In present study, only 2 RCTs ([@B31]; [@B44]) reported blinding of outcome assessment. The observer bias can be avoided by sufficient blinding. More independent assessors can be further used to increase the feasibility of blind assessment ([@B7]). Thirdly, 3 RCTs ([@B34]; [@B41]; [@B44]) formally registered. Clinical trial registration could help to minimize bias in selective reporting and improve the validity and value of the scientific evidence ([@B2]). Fourthly, intention to treat (ITT) analysis is a strategy to gather data as completely as possible on all randomized patients in line with their scheduled assessments ([@B45]). Four RCTs (Hermann-J et al., 2003; [@B34]; [@B41]; [@B44]) described whether they analyzed the data based on the ITT principle. Trials with incorrect or no ITT analysis may overestimate the results ([@B6]). Finally, various scales of fatigue were used as outcome measure in different trials. The evaluation of clinical efficacy rate is based on inconsistent scales, which restrict the validity and reliability. The quality of animal studies was considered to be moderate, suggesting that the results should be carefully interpreted. Fatigue can be divided into CFS and post-exercise fatigue in clinic. In the present analysis, all fatigue models are exhaustion, which may lead to ignore chronic process.

In addition, we cannot neglect the contribution of Korea and other countries worldwide in the study of ginseng in treatment of fatigue. Due to the limitation of language, the present study was not included studies which language was not English or Chinese. We can increase international cooperation to overcome the linguistic limitation.

Implications {#s4_3}
------------

The evidence available from present study supported the routine use of PGC for fatigue, whereas the safety still needs more data because only five of eight studies reported. Given the gap between limitations of the primary RCTs and the quality of RCTs, we recommend that further design of the RCTs should consult the CONSORT statement ([@B53]), which offer a standard way for authors to design, conduct, analyze, and interpret, and to assess the validity of results.

Currently, there is no gold standard for measuring fatigue. Various scales were used to measure fatigue in different studies. Some scales have been calibrated, and some are homemade. Measurement of fatigue is challenging. Due to the wide range of conceptualizations of the problem and the concurrent development of questionnaires for many specific diseases, many questionnaires are used to measure fatigue. A comprehensive fatigue measurement, such as the Fatigue Severity Scale ([@B43]), Piper Fatigue Scale ([@B59]), or FACIT-F ([@B13]), assesses the impact of fatigue on daily activities and its severity. In addition, short fatigue measurements such as the POMS-B fatigue subscale ([@B52]) and the 7-item Patient Reported Outcome Measurement Information System Cancer Fatigue Short Form ([@B8]; [@B29]) mainly assess severity of fatigue. The fatigue measurement precision with a comprehensive measure was greater than that with short fatigue measurement in evaluating moderate to severe fatigue, whereas the short fatigue measurement performed better in evaluating mild fatigue ([@B69]). Therefore, we should select the suitable fatigue measurements based on the research requirements.

Degree and scope of debilitating fatigue is a core component of health care where chronic diseases are receiving increasing attention. Current acute disease research models are not enough to solve chronic disorders affecting multiple regulatory systems and present complex constellations of symptoms. The identification of objective markers consistently associated with CFS is an important goal in relation to diagnosis and treatment, as the current case definitions are based entirely on physical signs and symptoms. Since the human body is an autonomous, fully integrated, and self-regulating system, it is not surprising that even localized muscle fatigue can present systemic biomarkers. There is a growing study devoted to understanding the biology of fatigue. Recognition of CFS biomarkers is an important part of this work. A complex construct of symptoms emerges from alterations and/or dysfunctions in the nervous, endocrine, and immune systems. Biomarkers, distributing across these systems, constituted complex biological networks. The acquisition of biomarkers required a comprehensive biological network-based analysis of fatigue biology ([@B42]). In addition, molecular aberrations observed in many CFS blood cell studies provided an opportunity to develop diagnostic analysis of blood samples. With the development of micro/nanofabrication, direct electrical detection of cellular and molecular properties, microfluidics, and artificial intelligence techniques, a nano-electronics blood-based assay have been developed, which can potentially establish diagnostic biomarkers and drug screening platform for CFS ([@B18]).

Preclinical research is the key to convert preclinical data into clinical data ([@B62]). However, there is growing concern that poor experimental design and transparent reporting lead to frequent failure of translating preclinical discoveries into new therapies for human diseases ([@B30]). In present study, the quality of including animal studies was moderate. We recommend that further design of the studies should consult the ARRIVE guidelines ([@B39]) and use appropriate animals, random allocation, model blinded induction, and outcomes blinded assessment to improve the accuracy of the results.

PGC acted through complex, multicompound, multitarget, and multipathway mechanisms in fatigue and might prove to be of great value in further clinical trials. The possible mechanisms of PGC for fatigue are summarized as follows: (1) Antioxidant stress: PGC passed through the injured membrane, improved the activity of GSH-Px, CAT, and SOD, scavenged hydroxyl radical, and reduced the excessive ROS, and thus preventing lipid oxidation and protecting the corpuscular membrane to reduce the release of LDH, MDA, and CK into the serum ([@B71]; [@B82]). Another mechanism might involve the nitric oxide pathway. NOS, a pro-oxidative enzyme, increased the production of toxic oxidant peroxynitrite. PGC decreased NOS and prevented peroxynitrite-induced mitochondrial dysfunction and lipid peroxidation ([@B38]); (2) Regulation of carbohydrate metabolism: PGC increased the proportion of energy supplied by fat and promoted gluconeogenesis to improve hepatic glycogen storage. PGC enhanced the delivery of glucose by increasing capillary perfusion and plasma glucose concentration and increased the permeability of the muscle membrane of glucose to increase the muscle glucose uptake during exercise ([@B72]; [@B51]). A reduced rate of hepatic and muscle glycogen break-down and a greater potential for fatty acid metabolism could maintain blood glucose level, and thus enhancing exercise capacity ([@B19]); (3) Delaying the accumulation of metabolites: With the accumulation of BUN and BLA, the pH in muscle tissue and blood reduced, which could obstruct the transmission of excitation at neuromuscular junctions, reduce the maximum tension and sustainability of muscle tissue, and hinder the process of sugar supply. PGC increased the LDH activity and the glycogen levels and retarded the accumulation of BUN and BLA ([@B54]; [@B14]); (4) Promotion of mitochondrial function: SDH is a key enzyme associated with the regulation of the tricarboxylic acid cycle, catalyzing the synthesis of ATP. In addition, Na^+^-K^+^-ATPase and Ca^2+^-Mg^2+^-ATPase are crucial enzymes to degrade ATP. NRF-1 and TFAM are positive regulators of transcription. PGC improved SDH, Na^+^-K^+^-ATPase, and Ca^2+^Mg^2+^-ATPase activities. PGC enhanced the mRNA expression of NRF-1 and TFAM and increased the mtDNA content, and thereby enhancing mitochondrial function and producing more ATP for energy supplementation ([@B14]); (5) Neuroprotection and antiapoptosis: PGC had a protective effect against MPTP-induced apoptosis in the mouse substantial nigra. This anti-apoptotic effect of PGC may be attributed to enhanced expression of Bcl-2 and Bcl-xl, reduced expression of bax and nitric oxide synthase, and inhibited activation of caspase-3 ([@B61]); (6) Regulation of neurotransmitter disorder: PGC decreased GABA and 5-HT levels, thereby increasing central nervous system excitability. PGC decreased the activity of acetylcholinesterase, maintained normal Ach and norepinephrine levels in cholinergic neurons, and enhanced the level of DA in the hippocampus ([@B21]; [@B9]).

Conclusions {#s5}
===========

The findings of present study demonstrated that PGC exerted anti-fatigue function, mainly through antioxidant stress, regulation of carbohydrate metabolism, delaying the accumulation of metabolites, promotion of mitochondrial function, neuroprotection and antiapoptosis, and regulation of neurotransmitter disorder. And the findings supported, at least to an extent, the use of PGC for fatigue.
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